Work with thought leaders and academic experts in pharmacology
Companies can greatly benefit from working with experts in the field of Pharmacology. These researchers possess in-depth knowledge of drug interactions, mechanisms of action, and therapeutic applications. By collaborating with them, companies can enhance their research and development efforts, gain insights into new drug targets, optimize drug formulations, and improve clinical trial design. Pharmacology experts can also provide valuable guidance in regulatory affairs, ensuring compliance with safety and efficacy standards. Additionally, their expertise can help companies identify potential drug-drug interactions and adverse effects, leading to safer and more effective medications. Overall, partnering with Pharmacology thought leaders can accelerate innovation, improve product quality, and drive business growth.
Researchers on NotedSource with backgrounds in pharmacology include Aimee Eggler, Regan Hamel, Dr. Everson A Nunes, Ph.D., Dushani L. Palliyaguru, Ph.D., Denver Ncube, Ph.D., Susan Song, MD/PhD, Katie Barr, Jeffrey Townsend, Lindsay Webb, PhD, Laura Schulze, Nora S Vyas, Ph.D., Marie Mooney, PhD, Yuri Bukhtiyarov, and Javier O. Morales.
Aimee Eggler
Professor of Chemistry and Biochemistry at Villanova University
Most Relevant Research Interests
Other Research Interests (18)
About
Most Relevant Publications (1+)
25 total publications
Solving the Problem of Assessing Synergy and Antagonism for Non-Traditional Dosing Curve Compounds Using the DE/ZI Method: Application to Nrf2 Activators
Frontiers in Pharmacology / Jun 07, 2021
Repash, E. M., Pensabene, K. M., Palenchar, P. M., & Eggler, A. L. (2021). Solving the Problem of Assessing Synergy and Antagonism for Non-Traditional Dosing Curve Compounds Using the DE/ZI Method: Application to Nrf2 Activators. Frontiers in Pharmacology, 12. https://doi.org/10.3389/fphar.2021.686201
See Full Profile
Regan Hamel
Senior bioinformatics scientist, specializing in single cell omics in the context of cellular reprogramming and neuroinflammation
Most Relevant Research Interests
Other Research Interests (12)
About
Most Relevant Publications (1+)
12 total publications
Combination of In Situ Lcn2 pRNA-RNAi Nanotherapeutics and iNSC Transplantation Ameliorates Experimental SCI in Mice
Molecular Therapy / Dec 01, 2020
Braga, A., Bandiera, S., Verheyen, J., Hamel, R., Rutigliani, C., Edenhofer, F., Smith, J. A., & Pluchino, S. (2020). Combination of In Situ Lcn2 pRNA-RNAi Nanotherapeutics and iNSC Transplantation Ameliorates Experimental SCI in Mice. Molecular Therapy, 28(12), 2677–2690. https://doi.org/10.1016/j.ymthe.2020.08.001
See Full Profile
Dr. Everson A Nunes, Ph.D.
Post-Doctoral Fellow at McMaster University | former Associate Professor - Physiological Sciences
Most Relevant Research Interests
Other Research Interests (39)
About
Most Relevant Publications (2+)
97 total publications
Age- and gender-related changes in glucose homeostasis in glucocorticoid-treated rats
Canadian Journal of Physiology and Pharmacology / Oct 01, 2014
dos Santos, C., Ferreira, F. B. D., Gonçalves-Neto, L. M., Taboga, S. R., Boschero, A. C., & Rafacho, A. (2014). Age- and gender-related changes in glucose homeostasis in glucocorticoid-treated rats. Canadian Journal of Physiology and Pharmacology, 92(10), 867–878. https://doi.org/10.1139/cjpp-2014-0259
Implications of Palmitoleic Acid (Palmitoleate) On Glucose Homeostasis, Insulin Resistance and Diabetes
Current Drug Targets / Mar 30, 2017
Nunes, E., & Rafacho, A. (2017). Implications of Palmitoleic Acid (Palmitoleate) On Glucose Homeostasis, Insulin Resistance and Diabetes. Current Drug Targets, 18(6), 619–628. https://doi.org/10.2174/1389450117666151209120345
See Full Profile
Denver Ncube, Ph.D.
Computational biologist/bioinformatician with a passion for extracting meaningful insight from complex biological data.
Most Relevant Research Interests
Other Research Interests (4)
About
Most Relevant Publications (1+)
6 total publications
Comparative Hepatotoxicity of Fluconazole, Ketoconazole, Itraconazole, Terbinafine, and Griseofulvin in Rats
Journal of Toxicology / Jan 01, 2017
Khoza, S., Moyo, I., & Ncube, D. (2017). Comparative Hepatotoxicity of Fluconazole, Ketoconazole, Itraconazole, Terbinafine, and Griseofulvin in Rats. Journal of Toxicology, 2017, 1–9. https://doi.org/10.1155/2017/6746989
See Full Profile
Katie Barr
Bioinformatician and developer with strong academic and commercial experience
Most Relevant Research Interests
Other Research Interests (11)
About
Most Relevant Publications (1+)
9 total publications
Deep Tissue Translocation of Graphene Oxide Sheets in Human Glioblastoma 3D Spheroids and an Orthotopic Xenograft Model
Advanced Therapeutics / Oct 09, 2020
de Lázaro, I., Sharp, P., Gurcan, C., Ceylan, A., Stylianou, M., Kisby, T., Chen, Y., Vranic, S., Barr, K., Taheri, H., Ozen, A., Bussy, C., Yilmazer, A., & Kostarelos, K. (2020). Deep Tissue Translocation of Graphene Oxide Sheets in Human Glioblastoma 3D Spheroids and an Orthotopic Xenograft Model. Advanced Therapeutics, 4(1). Portico. https://doi.org/10.1002/adtp.202000109
See Full Profile
Jeffrey Townsend
Professor of Biostatistics and Ecology & Evolutionary Biology
Most Relevant Research Interests
Other Research Interests (52)
About
Most Relevant Publications (1+)
207 total publications
Retrospective evidence for a biological cost of vancomycin resistance determinants in the absence of glycopeptide selective pressures
Journal of Antimicrobial Chemotherapy / Jan 07, 2011
Johnsen, P. J., Townsend, J. P., Bohn, T., Simonsen, G. S., Sundsfjord, A., & Nielsen, K. M. (2011). Retrospective evidence for a biological cost of vancomycin resistance determinants in the absence of glycopeptide selective pressures. Journal of Antimicrobial Chemotherapy, 66(3), 608–610. https://doi.org/10.1093/jac/dkq512
See Full Profile
Lindsay Webb, PhD
Immunologist and cancer biologist passionate about driving innovative research to improve patient health
Most Relevant Research Interests
Other Research Interests (6)
About
Most Relevant Publications (3+)
11 total publications
203 A membrane-tethered IL-15/IL-15 receptor fusion protein enhances the persistence and efficacy of CD70-targeted TRuC-T cells
Journal for ImmunoTherapy of Cancer / Nov 01, 2021
Ding, J., Webb, L., Patterson, T., Fleury, M., Zieba, A., Horton, H., Hofmeister, R., Gutierrez, D., & Tighe, R. (2021). 203 A membrane-tethered IL-15/IL-15 receptor fusion protein enhances the persistence and efficacy of CD70-targeted TRuC-T cells. Journal for ImmunoTherapy of Cancer, 9(Suppl 2), A214–A214. https://doi.org/10.1136/jitc-2021-sitc2021.203
173 Expression of a membrane-tethered IL-15/IL-15 receptor fusion protein enhances the persistence of MSLN-targeted TRuC-T cells
Journal for ImmunoTherapy of Cancer / Nov 01, 2021
Fleury, M., McCarthy, D., Horton, H., Anderson, C., Watt, A., Zieba, A., Webb, L., Ding, J., Tighe, R., Hofmeister, R., & Gutierrez, D. (2021). 173 Expression of a membrane-tethered IL-15/IL-15 receptor fusion protein enhances the persistence of MSLN-targeted TRuC-T cells. Journal for ImmunoTherapy of Cancer, 9(Suppl 2), A185–A185. https://doi.org/10.1136/jitc-2021-sitc2021.173
757 M9657, a novel tumor-targeted conditional anti-CD137 agonist displays MSLN-dependent anti-tumor immunity
Journal for ImmunoTherapy of Cancer / Nov 01, 2021
Xu, C., Rabinovich, B., Deshpande, A., Zhou, X., Pipp, F. C., Schweickhardt, R., Webb, L., Yalavarthi, S., Bourin, C., Ghatak, P., Safi, B., Wollerton, F., Brewis, N., Munoz-Olaya, J., Belousova, N., Alimzhanov, M., Hubensack, M., Halle, J.-P., Blaukat, A., & Moisan, J. (2021). 757 M9657, a novel tumor-targeted conditional anti-CD137 agonist displays MSLN-dependent anti-tumor immunity. Journal for ImmunoTherapy of Cancer, 9(Suppl 2), A792–A792. https://doi.org/10.1136/jitc-2021-sitc2021.757
See Full Profile
Laura Schulze
Passionate mental health researcher with a PhD in Neuroscience, dedicated to fostering innovation and empathy in accessible and holistic mental health care.
Most Relevant Research Interests
Other Research Interests (2)
About
Most Relevant Publications (4+)
8 total publications
Effect of antipsychotic pharmacotherapy on clinical outcomes of intermittent theta-burst stimulation for refractory depression
Journal of Psychopharmacology / Nov 11, 2016
Schulze, L., Remington, G., Giacobbe, P., Kennedy, S. H., Blumberger, D. M., Daskalakis, Z. J., & Downar, J. (2016). Effect of antipsychotic pharmacotherapy on clinical outcomes of intermittent theta-burst stimulation for refractory depression. Journal of Psychopharmacology, 31(3), 312–319. https://doi.org/10.1177/0269881116675516
Cognitive safety of dorsomedial prefrontal repetitive transcranial magnetic stimulation in major depression
European Neuropsychopharmacology / Jul 01, 2016
Schulze, L., Wheeler, S., McAndrews, M. P., Solomon, C. J. E., Giacobbe, P., & Downar, J. (2016). Cognitive safety of dorsomedial prefrontal repetitive transcranial magnetic stimulation in major depression. European Neuropsychopharmacology, 26(7), 1213–1226. https://doi.org/10.1016/j.euroneuro.2016.04.004
Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching
European Neuropsychopharmacology / Sep 01, 2013
Agid, O., Schulze, L., Arenovich, T., Sajeev, G., McDonald, K., Foussias, G., Fervaha, G., & Remington, G. (2013). Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching. European Neuropsychopharmacology, 23(9), 1017–1022. https://doi.org/10.1016/j.euroneuro.2013.04.010
Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report
Neuropsychopharmacology / Apr 29, 2020
Dunlop, K., Rizvi, S. J., Kennedy, S. H., Hassel, S., Strother, S. C., Harris, J. K., Zamyadi, M., Arnott, S. R., Davis, A. D., Mansouri, F., Schulze, L., Ceniti, A. K., Lam, R. W., Milev, R., Rotzinger, S., Foster, J. A., Frey, B. N., Parikh, S. V., Soares, C. N., … Downar, J. (2020). Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report. Neuropsychopharmacology, 45(8), 1390–1397. https://doi.org/10.1038/s41386-020-0688-x
See Full Profile
Nora S Vyas, Ph.D.
Associate Professor of Mental Health, with interest in civic engagement and partnerships
Most Relevant Research Interests
Other Research Interests (24)
About
Most Relevant Publications (2+)
30 total publications
Recent Developments in Neurochemical Imaging in Schizophrenia: An Update
Current Medicinal Chemistry / Jan 01, 2013
S. Vyas, N., H. Patel, N., Herscovitch, P., K. Puri, B., & Lanzenberger, R. (2013). Recent Developments in Neurochemical Imaging in Schizophrenia: An Update. Current Medicinal Chemistry, 20(3), 351–356. https://doi.org/10.2174/092986713804870765
Can genetics inform the management of cognitive deficits in schizophrenia?
Journal of Psychopharmacology / Feb 10, 2012
Vyas, N. S., Shamsi, S. A., Malhotra, A. K., Aitchison, K. J., & Kumari, V. (2012). Can genetics inform the management of cognitive deficits in schizophrenia? Journal of Psychopharmacology, 26(3), 334–348. https://doi.org/10.1177/0269881111434623
See Full Profile
Marie Mooney, PhD
Assistant Professor, University of North Florida specializing in Genetics, Neuroscience, and Bioinformatics
Most Relevant Research Interests
Other Research Interests (17)
About
Most Relevant Publications (1+)
14 total publications
Anti-tumor effect of sulfasalazine in neuroblastoma
Biochemical Pharmacology / Apr 01, 2019
Mooney, M. R., Geerts, D., Kort, E. J., & Bachmann, A. S. (2019). Anti-tumor effect of sulfasalazine in neuroblastoma. Biochemical Pharmacology, 162, 237–249. https://doi.org/10.1016/j.bcp.2019.01.007
See Full Profile
Yuri Bukhtiyarov
Expert in small molecule drug discovery and preclinical/early clinical development of drug candidates with a track record of accomplishments and publications in peer-reviewed scientific journals
Most Relevant Research Interests
Other Research Interests (22)
About
Most Relevant Publications (1+)
39 total publications
Regulation of Sphingomyelin Phosphodiesterase Acid-Like 3A Gene (SMPDL3A) by Liver X Receptors
Molecular Pharmacology / Jul 18, 2012
Noto, P. B., Bukhtiyarov, Y., Shi, M., McKeever, B. M., McGeehan, G. M., & Lala, D. S. (2012). Regulation of Sphingomyelin Phosphodiesterase Acid-Like 3A Gene (SMPDL3A) by Liver X Receptors. Molecular Pharmacology, 82(4), 719–727. https://doi.org/10.1124/mol.112.078865
See Full Profile
Javier O. Morales
Professor of drug delivery and pharmaceutical product development at University of Chile
Most Relevant Research Interests
Other Research Interests (30)
About
Most Relevant Publications (12+)
63 total publications
Nanoparticles for the Treatment of Wounds
Current Pharmaceutical Design / Oct 07, 2015
Oyarzun-Ampuero, F., Vidal, A., Concha, M., Morales, J., Orellana, S., & Moreno-Villoslada, I. (2015). Nanoparticles for the Treatment of Wounds. Current Pharmaceutical Design, 21(29), 4329–4341. https://doi.org/10.2174/1381612821666150901104601
Buccal delivery of small molecules and biologics: of mucoadhesive polymers, films, and nanoparticles
Current Opinion in Pharmacology / Oct 01, 2017
Morales, J. O., & Brayden, D. J. (2017). Buccal delivery of small molecules and biologics: of mucoadhesive polymers, films, and nanoparticles. Current Opinion in Pharmacology, 36, 22–28. https://doi.org/10.1016/j.coph.2017.07.011
Novel strategies for the buccal delivery of macromolecules
Drug Development and Industrial Pharmacy / Mar 10, 2014
Morales, J. O., & McConville, J. T. (2014). Novel strategies for the buccal delivery of macromolecules. Drug Development and Industrial Pharmacy, 40(5), 579–590. https://doi.org/10.3109/03639045.2014.892960
Protein-coated nanoparticles embedded in films as delivery platforms
Journal of Pharmacy and Pharmacology / Mar 29, 2013
Morales, J. O., Ross, A. C., & McConville, J. T. (2013). Protein-coated nanoparticles embedded in films as delivery platforms. Journal of Pharmacy and Pharmacology, 65(6), 827–838. https://doi.org/10.1111/jphp.12046
Buccal and Sublingual Vaccines: A Review on Oral Mucosal Immunization and Delivery Systems
Vaccines / Oct 14, 2021
Trincado, V., Gala, R. P., & Morales, J. O. (2021). Buccal and Sublingual Vaccines: A Review on Oral Mucosal Immunization and Delivery Systems. Vaccines, 9(10), 1177. https://doi.org/10.3390/vaccines9101177
A design of experiments to optimize a new manufacturing process for high activity protein-containing submicron particles
Drug Development and Industrial Pharmacy / Jan 08, 2013
Morales, J. O., Joks, G. M., Lamprecht, A., Ross, A. C., & McConville, J. T. (2013). A design of experiments to optimize a new manufacturing process for high activity protein-containing submicron particles. Drug Development and Industrial Pharmacy, 39(11), 1793–1801. https://doi.org/10.3109/03639045.2012.737332
Organic and Inorganic Nanoparticles for Prevention and Diagnosis of Gastric Cancer
Current Pharmaceutical Design / Oct 07, 2015
Oyarzun-Ampuero, F., Guerrero, A., Hassan-Lopez, N., Morales, J., Bollo, S., Corvalan, A., Quest, A., & Kogan, M. (2015). Organic and Inorganic Nanoparticles for Prevention and Diagnosis of Gastric Cancer. Current Pharmaceutical Design, 21(29), 4145–4154. https://doi.org/10.2174/1381612821666150901095538
Novel Nanostructured Polymeric Carriers to Enable Drug Delivery for Cardiovascular Diseases
Current Pharmaceutical Design / Oct 07, 2015
Morales, J., Sepulveda-Rivas, S., Oyarzun-Ampuero, F., Lavandero, S., & Kogan, M. (2015). Novel Nanostructured Polymeric Carriers to Enable Drug Delivery for Cardiovascular Diseases. Current Pharmaceutical Design, 21(29), 4276–4284. https://doi.org/10.2174/1381612821666150901103556
Selected abstracts from Excipient Fest 2017
Drug Development and Industrial Pharmacy / Dec 25, 2017
Selected abstracts from Excipient Fest 2017. (2017). Drug Development and Industrial Pharmacy, 44(5), 868–871. https://doi.org/10.1080/03639045.2017.1410331
Book Review
Drug Development and Industrial Pharmacy / Jan 31, 2014
Morales, J. O. (2014). Book Review. Drug Development and Industrial Pharmacy, 41(4), 529–529. https://doi.org/10.3109/03639045.2014.884131
Book Review
Drug Development and Industrial Pharmacy / Mar 07, 2014
Felton, L. A. (2014). Book Review. Drug Development and Industrial Pharmacy, 40(8), 1132–1132. https://doi.org/10.3109/03639045.2014.895376
Preface for buccal drug delivery theme issue
Drug Development and Industrial Pharmacy / Feb 27, 2014
Morales, J. O., & McConville, J. T. (2014). Preface for buccal drug delivery theme issue. Drug Development and Industrial Pharmacy, 40(5), 577–578. https://doi.org/10.3109/03639045.2014.892961
See Full Profile
Example pharmacology projects
How can companies collaborate more effectively with researchers, experts, and thought leaders to make progress on pharmacology?
Optimizing Drug Formulations
A pharmaceutical company can collaborate with a Pharmacology expert to optimize the formulation of a drug, ensuring its stability, bioavailability, and therapeutic efficacy. The researcher can provide insights into the physicochemical properties of the drug, recommend suitable excipients, and suggest formulation strategies to enhance drug delivery and absorption.
Identifying New Drug Targets
By partnering with a Pharmacology researcher, a biotechnology company can identify novel drug targets for various diseases. The expert can analyze disease mechanisms, molecular pathways, and receptor interactions to identify potential therapeutic targets. This collaboration can lead to the development of innovative drugs with improved efficacy and specificity.
Improving Clinical Trial Design
A contract research organization (CRO) can collaborate with a Pharmacology expert to improve the design of clinical trials. The researcher can provide insights into appropriate dosing regimens, patient selection criteria, and outcome measures. This collaboration can enhance the efficiency and reliability of clinical trials, leading to faster drug approvals and reduced development costs.
Assessing Drug Safety and Efficacy
A pharmaceutical company can work with a Pharmacology expert to assess the safety and efficacy of their drugs. The researcher can conduct preclinical studies, evaluate drug-drug interactions, and assess potential adverse effects. This collaboration can help identify and mitigate safety risks, ensuring the development of safe and effective medications.
Navigating Regulatory Affairs
Companies can collaborate with Pharmacology experts to navigate the complex landscape of regulatory affairs. These researchers can provide guidance on regulatory requirements, assist in preparing documentation for regulatory submissions, and ensure compliance with safety and efficacy standards. This collaboration can streamline the regulatory process and expedite the approval of new drugs.